<DOC>
	<DOCNO>NCT02619851</DOCNO>
	<brief_summary>This clinical trial Phase II control , parallel , open-label trial , design test efficacy safety ALLO-ASC-DFU conventional therapy Deep Second-degree burn wound subject .</brief_summary>
	<brief_title>A Clinical Trial Evaluate Safety Efficacy ALLO-ASC-DFU Second Deep Degree Burn Injury Subjects</brief_title>
	<detailed_description>ALLO-ASC-DFU hydrogel sheet contain allogenic adipose-derived mesenchymal stem cell . Adipose-derived stem cell anti-inflammatory effect release growth factor vascular endothelial growth factor ( VEGF ) hepatocyte growth factor ( HGF ) , enhance wound heal regeneration new tissue , finally may provide new option treat Deep Second-degree burn wound .</detailed_description>
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Burns</mesh_term>
	<criteria>1 . Subject 18 year age old . 2 . Subjects deep seconddegree burn wound ≥100cm2 . 3 . TBSA ( Total burn surface area ) ≤ 30 % 4 . Negative Urine betaHCG woman childbearing age . 5 . Subject able give write informed consent prior study start comply study requirement . 1 . Subject enrol another clinical study within 30 day screen . 2 . Subjects allergic hypersensitive reaction bovinederived protein fibrin glue . 3 . Subjects receive steroid , immunosuppressive , anticoagulant long term 4 . Subjects active infection . 5 . Subjects hemorrhagic hemocoagulative disease . 6 . Subjects unwilling use `` effective '' method contraception study . 7 . Subjects history malignant tumor within last five year , currently undergo . 8 . Subjects pregnant breastfeeding . 9 . Subjects consider significant disease impact wound heal investigator 10 . Burn wound present part face . 11 . Subjects consider suitable study investigator . 12 . Subjects able understand objective study comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>